Dolutegravir is an antiviral agent used for the treatment of HIV-1 infections in combination with other antiretroviral agents. Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI).
- Mechanism
- Curator reviewed · 1 reference
Dolutegravir is an HIV-1 antiviral agent. It inhibits HIV integrase by binding to the active site and blocking the strand transfer step of retroviral DNA integration in the host cell. The strand transfer step is essential in the HIV replication cycle and results in the inhibition of viral activity. Dolutegravir has a mean EC50 value of 0.5 nM (0.21 ng/mL) to 2.1 nM (0.85 ng/mL) in peripheral blood mononuclear cells (PBMCs) and MT-4 cells.
- Primary indication
- Dolutegravir is indicated in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection that comply with the characteristics of being adults or children aged 12 years and older and present at...Curator reviewed · 9 structured indications
- Formula / weight
- C20H19F2N3O5 · 419.3788 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2013 · European Union, 2016
- Code names
- GSK1349572 · GSK572 · S-349572 · S/GSK1349572
- Brand names
Resolves to
RHWKPHLQXYSBKR-BMIGLBTASA-NSMILES[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2What you can answer from here — as of September 25, 2026
Which drugs share a target with Dolutegravir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account